Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Implex was a medical device company specializing in the development and manufacture of advanced orthopedic implants using its proprietary Hedrocel porous tantalum technology. The company's core innovation, Hedrocel, is a structural biomaterial that mimics the properties of trabecular bone, facilitating rapid bone ingrowth and providing superior mechanical stability. Implex's product portfolio included components for hip and knee arthroplasty, as well as spinal and reconstructive applications. In 2004, the company was acquired by Zimmer Holdings for approximately $108 million, integrating its porous metal technology into Zimmer's global orthopedic offerings. Today, the technology is marketed under the 'Trabecular Metal' brand by Zimmer Biomet and remains a gold standard in porous metal implants.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Implex.